Government-Owned Inventions; Availability for Licensing, 39443-39444 [2017-17438]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 159 / Friday, August 18, 2017 / Notices
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: August 14, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–17430 Filed 8–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2017–17428 Filed 8–17–17; 8:45 am]
mstockstill on DSK30JT082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group Epidemiology, Prevention and
Behavior Research Review Subcommittee.
Date: October 23, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference
Rooms, 5635 Fishers Lane, Rockville, MD
20852.
Contact Person: Anna Ghambaryan, M.D.,
Ph.D., Scientific Review Officer, Extramural
Project Review Branch, Office of Extramural
Activities, National Institute on Alcohol
Abuse and Alcoholism, National Institutes of
Health, 5635 Fishers Lane, Room 2019,
Rockville, MD 20852, 301–443–4032,
anna.ghambaryan@nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group Clinical, Treatment and
Health Services Research Review
Subcommittee.
Date: November 1, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference Room
508, 5635 Fishers Lane, Rockville, MD 20852
Contact Person: Ranga V. Srinivas, Ph.D.
Chief Extramural Project Review, Branch
17:47 Aug 17, 2017
Jkt 241001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Dated: August 14, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meetings
VerDate Sep<11>2014
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
5365 Fishers Lane, Room 2085, Rockville,
MD 20852, (301) 451–2067 srinivar@
mail.nih.gov.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., (301) 594–8730;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
(301) 496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Development of a Transferrable
Norwalk Virus Epitope and Detector
Monoclonal Antibody
Description of Technology
Noroviruses are now recognized as
the major cause of non-bacterial
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
39443
gastroenteritis in all age groups, and
efforts are underway to develop an
effective vaccine. The lack of a robust
cell culture system for human
noroviruses has complicated vaccine
development. Hence, norovirus virus
like particles (VLPs) have played an
important role in the understanding of
virus structure, immune response,
antigenic diversity, and vaccine design.
The development of monoclonal
antibodies (MAbs) against norovirus
VLPs has allowed the identification and
characterization of key antigenic sites of
the virus capsid and facilitated the
development of diagnostic assays.
During characterization of a panel of
MAbs raised against Norwalk virus
(NV), a prototype norovirus strain, the
inventors identified a monoclonal
antibody (MAbNV10) that proved useful
in the identification of NV in tissue and
in the characterization of an insertion
site in the feline calicivirus (FCV)
genome. The inventors mapped the
precise binding site of the MAb by
peptide screening and discovered that
the epitope could be expressed when
fused to other proteins. The sequence of
this peptide (epitope) along with the
detector antibody could be used as a
new way to tag proteins for functional
studies. The small size of the linear
epitope, along with the strong avidity of
the detector monoclonal antibody makes
this system especially useful for many
techniques, including
immunofluorescence, Western blot,
immunoprecipitation (including
‘‘pulldown’’ assays), and
immunohistochemistry. The inventors’
epitope system may be comparable to
that of the HA tag of influenza virus that
is widely used in molecular biology.
This technology is further described
in Parra et al., ‘‘Mapping and modeling
of a strain-specific epitope in the
Norwalk virus capsid inner shell,’’
Virology. 2016 May;492:232–41. doi:
10.1016/j.virol.2016.02.019. Epub 2016
Mar 21.
Materials available for licensing
comprise: (1) Hybridoma cell line NV10,
(2) Plasmid expressing NV10 epitope as
positive control, and (3) Plasmid
expressing the NV10 scFV.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Diagnostics
• Vaccines
Competitive Advantages
• Cross-reactive norovirus antibody
E:\FR\FM\18AUN1.SGM
18AUN1
39444
Federal Register / Vol. 82, No. 159 / Friday, August 18, 2017 / Notices
• Ease of manufacture
• Efficient norovirus detection
Development Stage
• In vivo data available (animal)
Inventors: Kim Green, Ph.D. (NIAID);
Gabriel Parra, Ph.D. (NIAID); Stanislav
Sosnovtsev, Ph.D. (NIAID); Karin Bok,
Ph.D. (NIAID); Carlos Sandoval-Jaime,
Ph.D. (NIAID); Eugenio Abente, Ph.D.
(NIAID)
Intellectual Property: HHS Reference
No. E–101–2013/0.
Licensing Contact: Peter Soukas, J.D.,
(301) 594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize norovirus diagnostics or
vaccines. For collaboration
opportunities, please contact Peter
Soukas, J.D., (301) 594–8730;
peter.soukas@nih.gov.
Dated: August 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–17438 Filed 8–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
mstockstill on DSK30JT082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel Contract Review.
Date: September 12, 2017.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, One
Democracy Plaza, Room 1037, 6701
VerDate Sep<11>2014
17:47 Aug 17, 2017
Jkt 241001
Democracy Boulevard, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Rahat (Rani) Khan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing,
Translational Sciences, 6701 Democracy
Blvd., Rm 1078, Bethesda, MD 20892, 301–
894–7319, khanr2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: August 14, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–17427 Filed 8–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; NIBIB Team-Based
R25 Review (2018/01).
Date: September 28, 2017.
Time: 09:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Ruixia Zhou, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Democracy Two Building, Suite
957, Bethesda, MD 20892, (301) 496–4773,
zhour@mail.nih.gov.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; T32–R25 Review
Meeting (2018/01).
Date: October 24, 2017.
Time: 09:30 a.m. to 7:00 p.m.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, 6707 Democracy
Blvd., Suite 959, Democracy Two, Bethesda,
MD 20892, (301) 451–3398, hayesj@
mail.nih.gov.
Dated: August 14, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–17429 Filed 8–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615–0120]
Agency Information Collection
Activities; Extension, Without Change,
of a Currently Approved Collection;
Free Training for Civics and
Citizenship of Adults, Form G–1190;
Civics and Citizenship Toolkit, Form
G–1515
U.S. Citizenship and
Immigration Services, Department of
Homeland Security.
ACTION: 30-Day notice.
AGENCY:
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration Services (USCIS) will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and clearance in accordance
with the Paperwork Reduction Act of
1995. The purpose of this notice is to
allow an additional 30 days for public
comments.
DATES: The purpose of this notice is to
allow an additional 30 days for public
comments. Comments are encouraged
and will be accepted until September
18, 2017. This process is conducted in
accordance with 5 CFR 1320.10.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, must be
directed to the OMB USCIS Desk Officer
via email at dhsdeskofficer@
omb.eop.gov. All submissions received
must include the agency name and the
OMB Control Number 1615–0120 in the
subject line.
You may wish to consider limiting the
amount of personal information that you
SUMMARY:
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 82, Number 159 (Friday, August 18, 2017)]
[Notices]
[Pages 39443-39444]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17438]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Soukas, J.D., (301) 594-8730;
peter.soukas@nih.gov. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD, 20852; tel. (301) 496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Development of a Transferrable Norwalk Virus Epitope and Detector
Monoclonal Antibody
Description of Technology
Noroviruses are now recognized as the major cause of non-bacterial
gastroenteritis in all age groups, and efforts are underway to develop
an effective vaccine. The lack of a robust cell culture system for
human noroviruses has complicated vaccine development. Hence, norovirus
virus like particles (VLPs) have played an important role in the
understanding of virus structure, immune response, antigenic diversity,
and vaccine design. The development of monoclonal antibodies (MAbs)
against norovirus VLPs has allowed the identification and
characterization of key antigenic sites of the virus capsid and
facilitated the development of diagnostic assays. During
characterization of a panel of MAbs raised against Norwalk virus (NV),
a prototype norovirus strain, the inventors identified a monoclonal
antibody (MAbNV10) that proved useful in the identification of NV in
tissue and in the characterization of an insertion site in the feline
calicivirus (FCV) genome. The inventors mapped the precise binding site
of the MAb by peptide screening and discovered that the epitope could
be expressed when fused to other proteins. The sequence of this peptide
(epitope) along with the detector antibody could be used as a new way
to tag proteins for functional studies. The small size of the linear
epitope, along with the strong avidity of the detector monoclonal
antibody makes this system especially useful for many techniques,
including immunofluorescence, Western blot, immunoprecipitation
(including ``pulldown'' assays), and immunohistochemistry. The
inventors' epitope system may be comparable to that of the HA tag of
influenza virus that is widely used in molecular biology.
This technology is further described in Parra et al., ``Mapping and
modeling of a strain-specific epitope in the Norwalk virus capsid inner
shell,'' Virology. 2016 May;492:232-41. doi: 10.1016/
j.virol.2016.02.019. Epub 2016 Mar 21.
Materials available for licensing comprise: (1) Hybridoma cell line
NV10, (2) Plasmid expressing NV10 epitope as positive control, and (3)
Plasmid expressing the NV10 scFV.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Diagnostics
Vaccines
Competitive Advantages
Cross-reactive norovirus antibody
[[Page 39444]]
Ease of manufacture
Efficient norovirus detection
Development Stage
In vivo data available (animal)
Inventors: Kim Green, Ph.D. (NIAID); Gabriel Parra, Ph.D. (NIAID);
Stanislav Sosnovtsev, Ph.D. (NIAID); Karin Bok, Ph.D. (NIAID); Carlos
Sandoval-Jaime, Ph.D. (NIAID); Eugenio Abente, Ph.D. (NIAID)
Intellectual Property: HHS Reference No. E-101-2013/0.
Licensing Contact: Peter Soukas, J.D., (301) 594-8730;
peter.soukas@nih.gov. Collaborative Research Opportunity: The National
Institute of Allergy and Infectious Diseases is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize norovirus
diagnostics or vaccines. For collaboration opportunities, please
contact Peter Soukas, J.D., (301) 594-8730; peter.soukas@nih.gov.
Dated: August 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-17438 Filed 8-17-17; 8:45 am]
BILLING CODE 4140-01-P
